Published in Clin Pharmacol Ther on November 02, 2011
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med (2014) 4.21
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
Co-ingestion of prescription opioids and other drugs among high school seniors: results from a national study. Drug Alcohol Depend (2012) 1.15
Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray. Neuroscience (2012) 0.91
Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Haematologica (2015) 0.86
Marijuana Legalization: Impact on Physicians and Public Health. Annu Rev Med (2015) 0.86
Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther (2014) 0.83
Is cannabis use associated with less opioid use among people who inject drugs? Drug Alcohol Depend (2015) 0.81
Clearing the smoke around medical marijuana. Clin Pharmacol Ther (2011) 0.80
Subgroups of musculoskeletal pain patients and their psychobiological patterns - the LOGIN study protocol. BMC Musculoskelet Disord (2012) 0.78
The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids. Pharmacol Biochem Behav (2012) 0.78
Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys. Psychopharmacology (Berl) (2015) 0.78
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology (2016) 0.77
Opioid and cannabinoid synergy in a mouse neuropathic pain model. Br J Pharmacol (2016) 0.77
Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal. J Pharmacol Exp Ther (2016) 0.77
Cannabis--a valuable drug that deserves better treatment. Mayo Clin Proc (2012) 0.77
Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug Alcohol Depend (2017) 0.77
Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs (2015) 0.76
The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther (2016) 0.76
Integrating cannabis into clinical cancer care. Curr Oncol (2016) 0.76
Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology (2017) 0.75
The role of cannabinoids in chronic pain patients remains hazy. Clin Pharmacol Ther (2012) 0.75
A survey of cannabis (marijuana) use and self-reported benefit in men with chronic prostatitis/chronic pelvic pain syndrome. Can Urol Assoc J (2014) 0.75
The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document. Clin J Pain (2015) 0.75
Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Devel Ther (2014) 0.75
The Current Landscape of Marijuana and Pharmacogenetics. Cureus (2017) 0.75
Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Mol Pain (2017) 0.75
Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med (2000) 5.12
Nicotine metabolism and intake in black and white smokers. JAMA (1998) 5.03
Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med (1983) 4.80
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr (1981) 3.72
Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control (1998) 3.47
Cotinine disposition and effects. Clin Pharmacol Ther (1983) 3.26
Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med (1986) 2.87
Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health (1988) 2.63
Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology (2007) 2.55
Drug interactions with tobacco smoking. An update. Clin Pharmacokinet (1999) 2.52
Apparent underreporting of cigarette consumption among Mexican American smokers. Am J Public Health (1990) 2.47
Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther (1984) 2.43
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health (1988) 2.16
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther (1982) 2.12
Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg (2015) 2.11
Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom (1991) 2.10
Sensitivity of ribonucleic acid and deoxyribonucleic acid viruses to different species of interferon in cell cultures. J Virol (1972) 2.09
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav (2000) 1.87
Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend (1993) 1.84
Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf (2001) 1.84
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med (1995) 1.82
Clonidine for smoking cessation. Cochrane Database Syst Rev (2004) 1.80
Misclassification of smoking status by self-reported cigarette consumption. Am Rev Respir Dis (1992) 1.79
Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet (1978) 1.79
Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies. J Clin Invest (1976) 1.78
Chronic developmental lead exposure reduces neurogenesis in adult rat hippocampus but does not impair spatial learning. Toxicol Sci (2005) 1.77
Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science (1994) 1.73
Sequence determination of the capsid protein gene and flanking regions of tobacco etch virus: Evidence for synthesis and processing of a polyprotein in potyvirus genome expression. Proc Natl Acad Sci U S A (1985) 1.70
Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther (2007) 1.70
Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav (1989) 1.64
Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther (1982) 1.60
Reducing tobacco addiction through tobacco product regulation. Tob Control (2004) 1.59
Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol (1997) 1.56
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther (1997) 1.53
Toward a comprehensive long term nicotine policy. Tob Control (2005) 1.52
Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health (1999) 1.52
Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther (2011) 1.52
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med (1989) 1.48
Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. JAMA (1986) 1.45
Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther (1987) 1.45
Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Drug Saf (1992) 1.43
Suicidal behavior and sexual/physical abuse among street youth. Child Abuse Negl (1998) 1.42
Cumulative radiation dose during hospitalization for aneurysmal subarachnoid hemorrhage. AJNR Am J Neuroradiol (2010) 1.42
Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am J Respir Crit Care Med (2001) 1.42
Medical students' views on selection tools for medical school--a mixed methods study. Ir Med J (2014) 1.41
Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol (1982) 1.41
Changes in plasma catecholamines after tonic-clonic seizures. Neurology (1984) 1.40
The use of biologic fluid samples in assessing tobacco smoke consumption. NIDA Res Monogr (1983) 1.39
Phencyclidine poisoning. JAMA (1975) 1.37
Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther (1985) 1.35
A proposal to develop meaningful labeling for cigarettes. JAMA (1994) 1.35
Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol (1997) 1.32
Advance directives are more likely among seniors asked about end-of-life care preferences. Arch Intern Med (1999) 1.32
Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users. Clin Pharmacol Ther (1981) 1.31
Recent studies of nicotine metabolism in humans. Pharmacol Biochem Behav (1988) 1.30
Atropine occlusion in the treatment of strabismic amblyopia and its effect upon the non-amblyopic eye. Ophthalmic Physiol Opt (1991) 1.28
Curative cerebrovascular reconstruction with the Pipeline embolization device: the emergence of definitive endovascular therapy for intracranial aneurysms. J Neurointerv Surg (2009) 1.28
Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther (2000) 1.26
Interaction of workplace demands and cardiovascular reactivity in progression of carotid atherosclerosis: population based study. BMJ (1997) 1.26
Clinical pharmacology of nicotine. Annu Rev Med (1986) 1.25
Nicotine exposure among nondependent smokers. Arch Gen Psychiatry (1990) 1.24
Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther (1993) 1.20
Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest (1994) 1.16
How a cigarette is smoked determines blood nicotine levels. Clin Pharmacol Ther (1983) 1.16
Mitogen-activated protein and tyrosine kinases in the activation of astrocyte volume-activated chloride current. J Neurosci (1998) 1.16
Environmental and drug-induced hyperthermia. Pathophysiology, recognition, and management. Emerg Med Clin North Am (1984) 1.16
Workshop on problem-based learning as a method for teaching clinical pharmacology and therapeutics in medical school. J Clin Pharmacol (1992) 1.15
The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav (1989) 1.13
Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis. Clin Nephrol (1979) 1.13
Nicotine elimination and tolerance in non-dependent cigarette smokers. Psychopharmacology (Berl) (1992) 1.12
Kindling modulates the IL-1beta system, TNF-alpha, TGF-beta1, and neuropeptide mRNAs in specific brain regions. Brain Res Mol Brain Res (2000) 1.12
Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther (1975) 1.12
Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin Pharmacol Ther (1984) 1.11
The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist. Br J Pharmacol (1988) 1.11
Cardiopulmonary catastrophes in drug-overdosed patients. Med Clin North Am (1979) 1.10
Nicotine and carbon monoxide intake from high- and low-yield cigarettes. Clin Pharmacol Ther (1984) 1.10
gamma-Aminobutyric acid(A) receptor subunit expression predicts functional changes in hippocampal dentate granule cells during postnatal development. J Neurochem (2001) 1.10
Clinical pharmacology of nicotine. Clin Dermatol (1998) 1.09
Disposition kinetics and effects of intravenous nicotine. Clin Pharmacol Ther (1980) 1.06
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther (2007) 1.06
Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. J Chromatogr (1993) 1.06
Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res (1989) 1.06
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav (1991) 1.05
Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther (1977) 1.04
Disposition kinetics and effects of menthol. Clin Pharmacol Ther (1999) 1.03
Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chem Res Toxicol (1992) 1.03
Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther (1988) 1.03
Blood cotinine levels as indicators of smoking treatment outcome. Clin Pharmacol Ther (1984) 1.02
Treating tobacco addiction--nicotine or no nicotine? N Engl J Med (1997) 1.02
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther (2012) 1.02
Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet (1980) 1.01
The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Drugs Aging (1996) 1.00
Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther (1979) 1.00
Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther (2000) 1.00